At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 127 enrolled
Drug / intervention
DCCR +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-Blind, Placebo-Controlled Study of Diazoxide Choline Controlled-Release Tablet (DCCR) in Patients With Prader-Willi Syndrome
In Brief
A Phase 3 clinical trial evaluating DCCR and Placebo for DCCR for Prader-Willi Syndrome. Completed, enrolled 127 participants across 29 sites in 2 countries.
Detailed Summary
The purpose of this is study is to evaluate the effects of DCCR (diazoxide choline controlled release tablets) in children and adults with Prader-Willi syndrome.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPrader-Willi Syndrome
CountriesUnited Kingdom, United States
Collaborators--
Timeline
Phase 3CompletedFinished
201820192020202120222023202420252026
First PostedFeb 2018
Enrollment StartMay 2018
Primary CompletionMay 2020
TodayJul 2026
First PostedFeb 22, 2018
Enrollment StartMay 9, 2018
Primary CompletionMay 1, 2020
TodayJul 2, 2026
Enrollment to primary: 2.0 yearsPosted 8.4 years ago
Interventions
DCCRdrug
Once daily oral administration
Placebo for DCCRdrug
Once daily oral administration